Hexvix (Hexaminolevulinate)

Hexvix is indicated for the diagnostic evaluation of patients with suspected or known non‑muscle invasive bladder cancer during cystoscopic examination.

• Enhances detection of carcinoma in situ and papillary tumors by fluorescence under blue light.
• Used as an adjunct to white‑light cystoscopy to improve lesion identification.
• Facilitates targeted biopsy of suspicious areas identified by fluorescence.
• May be employed in surveillance cystoscopies to assess recurrence after prior treatment.
• Supports intra‑operative decision‑making regarding resection extent.

• Hexvix contains hexaminolevulinate, a prodrug that is taken up preferentially by malignant urothelial cells and converted intracellularly to protoporphyrin IX. The accumulated porphyrin emits red fluorescence when illuminated with blue light (380–450 nm), highlighting cancerous tissue while normal bladder epithelium remains non‑fluorescent. This selective fluorescence enables clinicians to visualize and differentiate malignant lesions during cystoscopy. The process relies on the heme biosynthetic pathway, where hexaminolevulinate bypasses the rate‑limiting step, leading to higher porphyrin levels in dysplastic cells.

Adverse reactions to Hexvix are generally related to the intravesical administration and the photosensitizing properties of the agent.

Common

• Mild bladder irritation, including urgency, frequency, or dysuria.
• Transient hematuria or mild bleeding following instillation.
• Light sensitivity (photophobia) limited to the bladder area.
• Nausea or mild headache reported in a minority of patients.

Serious

• Severe allergic reaction such as anaphylaxis or angioedema.
• Persistent urinary retention requiring catheterization.
• Significant bladder wall inflammation or ulceration.

Before using Hexvix, clinicians should assess patient history and bladder condition to minimize potential risks.

• Confirm absence of active urinary tract infection before instillation.
• Avoid use in patients with known hypersensitivity to hexaminolevulinate or similar porphyrins.
• Ensure complete bladder emptying after the procedure to reduce residual solution.
• Monitor for signs of bladder irritation or allergic reaction during and after administration.
• Use caution in pregnant or breastfeeding women; safety data are limited.
• Do not combine with other intravesical agents unless specifically studied.
• Provide appropriate eye protection for staff handling the solution under blue light.

Hexvix may interact with other substances that affect bladder mucosa or photosensitivity.

Avoid

• Concurrent intravesical chemotherapy or immunotherapy agents not studied with Hexvix.
• Systemic photosensitizing drugs (e.g., porfimer sodium, aminolevulinic acid) during the same treatment period.
• Recent bladder surgery within 7 days, which may increase absorption and irritation.

Use with caution

• Anticoagulants or antiplatelet therapy, which may increase risk of hematuria.
• Drugs that alter bladder pH, potentially affecting drug uptake.
• Strong urinary tract irritants such as certain antibiotics or catheter materials.
• Concurrent use of topical agents containing porphyrins that could amplify fluorescence.
• Drugs that may interfere with heme synthesis pathways, potentially modifying fluorescence intensity.